# RD Saúde Rides GLP-1 Wave as Weight-Loss Drugs Power Growth

*GLP-1 weight-loss and diabetes drugs are reshaping RD Saúde’s business, positioning the retailer for a new cycle of data-driven growth.*

- Published: 2025-11-05
- Section: Insights
- Tags: Droga Raia, Drogasil, RD Saude
- URL: https://brazilstockguide.com/insights/rd-saude-glp1-growth-drogasil-droga-raia/

![Drogasil, pharmacy, retail, RD SAude](https://i0.wp.com/brazilstockguide.com/wp-content/uploads/2025/11/Drogasil.png?fit=1024%2C683&ssl=1)

![](https://i0.wp.com/brazilstockguide.com/wp-content/uploads/2025/10/selo-conference-call-683x1024.jpg?resize=683%2C1024&ssl=1)

**By Brazil Stock Guide –** The **GLP-1 drug class**, used for weight loss and diabetes treatment, has become the cornerstone of **RD Saúde**’s growth — the company behind Brazil’s largest pharmacy chains, **Drogasil** and **Droga Raia**. In the third quarter, these high-value medications sustained sales momentum, offset inflationary pressure, and reinforced the retailer’s dominance in the pharmacy sector.

CEO **Renato Raduan** told analysts the category already represents a **high-single-digit share of total sales** and could soon reach **double digits**, turning into a standalone business within the company’s portfolio.

### **From Trend to Structural Growth**

During the Q&A, **Luiz Guanais of BTG Pactual** pressed executives for details on GLP-1’s financial weight and its effect on working capital. Raduan said the drugs’ penetration reached **around 9%**, up from 5% a year earlier. “Once supply is normalized, it should exceed 10%. The potential is enormous,” he said.

The CEO added that RD now allows **six-month installment payments** for GLP-1 purchases, partly financed by pharmaceutical suppliers eager to expand access. “We’re expanding with responsibility — this isn’t a speculative cycle, it’s structural demand,” he said. He noted that a **six-to-seven-day reduction in inventory coverage** has offset any short-term cash impact, improving rotation and freeing capital.

### **One-Third of Brazil’s GLP-1 Sales Flow Through RD**

Investor Relations Director **Flávio Correia** emphasized the retailer’s market leadership: **roughly one-third of Brazil’s GLP-1 sales** already flow through RD’s network, serving **one million customers per month**. “That’s still far below the market’s potential,” he said, expecting volumes to rise as **new generics** increase supply and affordability.

Raduan added that GLP-1 could become “a category of its own, like hygiene or over-the-counter drugs,” arguing that RD’s scale, logistics, and digital integration give it a long-term competitive moat as consumer demand shifts toward metabolic health.

### **Digital Scale and Operational Efficiency**

Behind the pharmaceutical surge, RD is quietly building a **technology-driven moat** — merging logistics precision with digital reach. The company now completes **97% of deliveries within one hour**, with **27% of total sales coming from online channels**.

Executives also confirmed the opening of a **new distribution center in Espírito Santo**, aimed at restoring the performance of **Forbio**, RD’s wholesale unit, after a temporary loss of a major lab client. “We may have leaned too far toward protecting margins at any cost; now we’re rebalancing,” Raduan said.

He credited logistics teams for achieving the **lowest product-out-of-stock rate in five years** while trimming inventory days. “It’s a cycle of efficiency — better service, less capital tied up, fewer losses,” he said.

### **AI-Driven Productivity and Cost Discipline**

Analysts questioned whether RD’s corporate cost restructuring had limited its digital execution. Raduan pushed back, noting that the company recorded the **highest volume of digital releases in its history** over the past six months. He revealed that RD now uses **generative AI to support code development**, speeding up innovation and productivity.

He also highlighted improved customer metrics: **higher app satisfaction (NPS)** and **66% of digital sales from recurring customers**. “Efficiency can’t come at the expense of innovation,” he said. “Our goal is ambidexterity — operating efficiently while building the future.”

Raduan confirmed that RD improved its **loss and tax-on-sales ratio by 10 basis points** year-over-year, thanks to lower theft and better inventory control. “We reduced costs and simplified structures without compromising service or innovation,” he said.

With a **7.5% EBITDA margin** — the strongest third-quarter margin since the pandemic — RD proved it can **grow in complexity without losing financial discipline**, reassuring investors that its performance extends beyond the GLP-1 cycle.

### **Outlook: Scale, Data, and Discipline**

Looking ahead, Correia said RD entered 2025 “under pressure” but will exit “at a normalized and stable level,” ready for the next cycle. The company, he added, is combining **cash discipline with selective expansion**, maintaining a steady hand in a volatile market.

---

Source: Brazil Stock Guide, https://brazilstockguide.com/insights/rd-saude-glp1-growth-drogasil-droga-raia/
